NCT00136032View on ClinicalTrials.gov

Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women

NACompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
Growth Hormone Deficiency
Interventions
DRUG

Somatropin

Stratified based on age and estrogen status from 3 to 6 mcg/kg/day

DRUG

Placebo

Dosage based on age and estrogen status ranging from 3 to 6 mcg/kg/day

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT00136032 - Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women | Biotech Hunter | Biotech Hunter